Natco Pharma Limited has informed the Exchange about Investor Presentation
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has shared an investor presentation detailing its proposed acquisition of a 35.75% stake in Adcock Ingram Holdings, South Africa's second-largest pharmaceutical company, from the Bidvest Group (which will retain 64.25%). The total deal is valued at around ZAR 4 billion (roughly US$ 226 million or ₹2,000 crore) at ZAR 75 per share, implying a transaction multiple of about 7.8x EV/EBITDA on FY24 numbers. Adcock Ingram reported FY24 revenue of US$ 536 million and net profit of US$ 45 million, with a presence across prescription, OTC, hospital, and consumer healthcare segments and three manufacturing plants in South Africa. Natco highlighted potential synergies including distribution of its products through Adcock, affordable pharma offerings across Africa, cost efficiencies, and R&D cross-pollination. The deal gives Natco a strategic foothold in South Africa as a gateway to the broader African market.
This is a sizeable ₹2,000 crore cash deployment for Natco, adding meaningful international revenue and profit consolidation, but it also increases capital commitment and integration risk. Near-term stock reaction is likely to hinge on investor views on valuation, funding, and execution of the stated Africa-expansion synergies.